Glycaemic effects of non-statin lipid-lowering therapies

Collins, P. D. and Sattar, N. (2016) Glycaemic effects of non-statin lipid-lowering therapies. Current Cardiology Reports, 18, 133. (doi: 10.1007/s11886-016-0795-9) (PMID:27864787) (PMCID:PMC5116040)

129955.pdf - Published Version
Available under License Creative Commons Attribution.



Since the publication of the JUPITER trial, attention has been focused on the adverse glycemic effects of statin therapy. Although the modest increase in the risk of new diabetes mellitus is outweighed by the reduction in cardiovascular events for statins, emerging biochemical and genetic links between lipid metabolism and glycemic control raise the prospect of a broader diabetogenic effect of lipid-lowering therapies. For the novel and powerful PCSK9-inhibitor class available evidence does not support a major glycaemic effect with the results of large scale trials awaited although preliminary genetic data does suggest a link. In contrast, there is clear evidence of a diabetogenic effect for the now outdated but well-studied niacin. For ezetimibe and fibrates, evidence is scarce but currently broadly unconcerning. For now, the glycemic effects of lipid-lowering therapies should have a limited influence on clinical decision-making. Further study in this topical area is needed.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Collins, Dr Patrick and Sattar, Professor Naveed
Authors: Collins, P. D., and Sattar, N.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Current Cardiology Reports
Publisher:Springer US
ISSN (Online):1534-3170
Published Online:19 November 2016
Copyright Holders:Copyright © 2016 The Authors
First Published:First published in Current Cardiology Reports 18:133
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record